Compare Boston Scientific Corporation (BSX) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Tyson Foods, Inc. — how do they compare? Boston Scientific Corporation trades at $43.49 (market cap $66.37B), while Tyson Foods, Inc. trades at $58.1 (market cap $20.24B). The key difference: Boston Scientific Corporation is far larger — about 3.3× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays a 3.55% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | TSN | |
|---|---|---|
Market Cap | $66.37B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $108.14 | $68.75 |
52-Week Low | $42.63 | $50.72 |
Enterprise Value | $75.94B | $27.82B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Tyson Foods (TSN) trades at $57.92, up 0.16% on the day, with a bearish technical signal but mixed earnings performance including a Q1 2026 beat. The company shows modest revenue growth to $54.44 billion in 2025, though net margins are thin at 0.81%. Recent news highlights innovation in prepared foods and new leadership appointments, while analyst consensus leans bullish with a $68.80 price target.
The stock presents a value opportunity with low P/S and P/B ratios, but faces risks from volatile earnings, high debt, and competitive pressures. Upside depends on execution in value-added segments and cost management, with the current price offering a 19% discount to the consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
